Advertisement

Drugs

, Volume 20, Issue 6, pp 453–484 | Cite as

Antirheumatic Drugs: Clinical Pharmacology and Therapeutic Use

  • Gary L. Craig
  • W. Watson Buchanan
Review Article

Summary

With the exception of the treatment of gout and bacterial infections of joints, therapy in the rheumatic diseases remains inadequate. Although many patients gain symptomatic improvement on the drugs currently available, their impact on the underlying disease process remains uncertain. Hope for future therapeutic development is highest in rheumatoid arthritis with the second-line agents (e.g. gold, penicillamine), as unravelling their mechanism of action may lead to the design of more effective and less toxic medications. The cytotoxic agents appear to hold some promise in the therapy of vasculitis, but problems with their use have by no means been solved.

In the major problem area of Osteoarthritis, important gains are being made in the field of joint replacement, and the use of non-steroidal anti-inflammatory drugs in the interim has made symptoms more tolerable.

Obviously much remains to be done in research in the area of antirheumatic drugs.

Keywords

Rheumatoid Arthritis Clinical Pharmacology Gout Rheumatic Disease Allopurinol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abel, T.; Urowitz, M.B.; Smythe, H.A.; Keystone, E.C. and Norman, C.S.: Long-term effects of azathioprine in rheumatoid arthritis (abstract). Arthritis and Rheumatism 21: 539 (1978).Google Scholar
  2. Alexander, S. and Brendler, H.: Treatment of uric acid urolithiasis with allopurinol, a xanthine oxidase inhibitor. Journal of Urology 97: 340–343 (1967).PubMedGoogle Scholar
  3. Almeyda, J.; Barnardo, D.; Baker, H.; Levene, C.M. and Landells, J.W.: Structural and functional abnormalities of the liver in psoriasis before and during methotrexate therapy. British Journal of Dermatology 87: 623–631 (1972).PubMedGoogle Scholar
  4. Amatruda, T.T.; Hurat, M.M. and D’Esopo, N.D.: Certain endocrine and metabolic facets of the steroid withdrawal syndrome. Journal of Clinical Endocrinology and Metabolism 25: 1207–1217 (1965).PubMedGoogle Scholar
  5. Ameer, B. and Greenblatt, D.J.: Acetaminophen. Annals of Internal Medicine 87: 202–209 (1977).PubMedGoogle Scholar
  6. Arnett, F.C.; Whelton, J.C.; Zizic, T.M. and Stevens, M.B.: Methotrexate therapy in Polymyositis. Annals of the Rheumatic Diseases 32: 536–546 (1973).PubMedGoogle Scholar
  7. Auerbach, R.: Parenteral vs. oral folic acid antagonists. Archives of Dermatology 90: 553–557 (1964)PubMedGoogle Scholar
  8. Axelrod, L.: Glucocorticoid therapy. Medicine 55: 39–65 (1976).PubMedGoogle Scholar
  9. Ayres, J.W.; Weidler, D.J.; MacKichan, J.; Sakmar, E.; Hallmark, M.R.; Lemanowicz, E.F. and Wagner, J.G. Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man. European Journal of Clinical Pharmacology 12: 421–428 (1977).PubMedGoogle Scholar
  10. Bacon, P.A.; Tribe, C.R.; MacKenzie, J.C.; Verrier Jones, J.; Cumming, R.H. and Amer, B.: Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. Quarterly Journal of Medicine 45: 661–684 (1976).PubMedGoogle Scholar
  11. Bain, J.S.; El-Ghobarey, A.F.; Collins, R.M. and Sargent, N.W.: Tolmetin: an evaluation of a new preparation in the treatment of rheumatoid arthritis. British Journal of Clinical Practice 29: 208–210 (1975).PubMedGoogle Scholar
  12. Baker, H.: The influence of chloroquin and related drugs on psoriasis and keratoderma blenorrhagicum. British Journal of Dermatology 78: 161–166 (1966).Google Scholar
  13. Balogh, Z.; Papazoglou, S.N.; MacLeod, M. and Buchanan, W.W.: A crossover clinical trial of Piroxicam, indomethacin and ibuprofen in rheumatoid arthritis. Current Medical Research and Opinion 6: 148–153 (1979).PubMedGoogle Scholar
  14. Barker, J.D.; de Carle, D.J. and Auras, S.: Chronic excessive acetaminophen use and liver damage. Annals of Internal Medicine 87: 299–301 (1977).PubMedGoogle Scholar
  15. Barnardo, D.E.; Currey, H.L.F.; Mason, R.M.; Fox, W.R. and Weatherall, M.: Mefenamic acid and flufenamic acid compared with aspirin and Phenylbutazone in rheumatoid arthritis. British Journal of Medicine 2: 342–343 (1966).Google Scholar
  16. Berge, G.; Lundquist, A.; Rorsman, H. and Ackerman, M.: Liver biopsy in psoriasis. British Journal of Dermatology 82: 250–253 (1970).PubMedGoogle Scholar
  17. Bertrand, J.J.; Debeyre, N.; Kahn, M.F. and Ryckewaert, A.: La surveillance oculaire au cours des traitements prolongés par les anti-malariques de synthèse. Presse Medicale 76: 2139–2142 (1968).PubMedGoogle Scholar
  18. Beyer, K.H.; Russo, H.F.; Tillbon, E.K., Miller, A.K.; Verwey, W.F. and Gass, S.R.: “Benemid”, p(di-n-propylsulfamyl) benzoic acid: Its renal affinity and its elimination. American Journal of Physiology 166: 625–640 (1951).PubMedGoogle Scholar
  19. Bird, H.A. and Dixon, A. St.J.: Failure of D-penicillamine to affect peripheral joint involvement in ankylosing Spondylitis or HLA B27 associated arthropathy. Annals of the Rheumatic Diseases 36: 289 (letter) (1977).PubMedGoogle Scholar
  20. Birkhead, N.C.; Wagener, H.P. and Shick, R.M.: Treatment of temporal arteritis with adrenal corticosteroids. Journal of the American Medical Association 163: 821–827 (1957).PubMedGoogle Scholar
  21. Black, R.L.; O’Brien, W.M.; Van Scott, E.J.; Auerbach, R.; Eisen, A.Z. and Bunim, J.J.: Methotrexate therapy in psoriatic arthritis. Double-blind study on 21 patients. Journal of the American Medical Association 189: 743–747 (1964).PubMedGoogle Scholar
  22. Bloch, K.J.; Buchanan, W.W.; Wohl, M.J. and Bunim, J.J.: Sjögren’s syndrome: A clinical, pathological and serological study of sixty-two cases. Medicine 44: 187–231 (1965).PubMedGoogle Scholar
  23. Boardman, P.L. and Hart, F.D.: Side-effects of indomethacin. Annals of the Rheumatic Diseases 26: 127–132 (1967).PubMedGoogle Scholar
  24. Boss, G.R. and Seegmiller, J.E.: Hyperuricemia and gout: Classification, complications and management. New England Journal of Medicine 300: 1459–1467 (1979).PubMedGoogle Scholar
  25. Boston Collaborative Drug Surveillance Program: Excess of ampicillin rashes associated with allopurinol or hyperuricemia. New England Journal of Medicine 286: 505–507 (1972).Google Scholar
  26. Boston Collaborative Drug Surveillance Program: Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Journal of the American Medical Association 227: 1036–1040 (1974).Google Scholar
  27. Bower, R.J. and Damaino, R.E.: Human tolerability of Sulindac. Abstracts of the XIV International Congress of Rheumatology, San Francisco, p.254 (1977).Google Scholar
  28. Brooks, P.M.; Walker, J.J.: Lee, P.; Bell, A.M.; Buchanan, W.W., Fowler, P.D. and Anderson, JA. Erprobung eines neuen acetylsalicylsaure/paracetamol-praparates mit magensaftresistentem uberzug und zwei verschiedenen dosierungen von Phenylbutazone bei patienten mit primar chronischer polyarthritis anhard eines neuen bewertungsverfahren. Zeitschrift fur Rheumatologie 34: 350–365 (1975).PubMedGoogle Scholar
  29. Brooks, P.M.; Buchanan, W.W.; Grove, M. and Downie, W.W.: Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. Annals of the Rheumatic Diseases 35: 339–343 (1976a).PubMedGoogle Scholar
  30. Brooks, P.M.; Mason, DIR.; McNeil, R.; Anderson, J.A. and Buchanan, W.W.: An assessment of the therapeutic potential of azapropazone in rheumatoid arthritis. Current Medical Research and Opinion 4: 50–56 (1976b).PubMedGoogle Scholar
  31. Bucknall, R.C.; Balint, G. and Dawkins, R.L.: Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis. Scandinavian Journal of Rheumatology Supplement 28: 91–93 (1979).PubMedGoogle Scholar
  32. Bucknall, R.C.; Dixon, A. St.J.; Glick, E.N.; Woodland, J. and Zutshi, D.: Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. British Medical Journal 1: 600–602 (1975).PubMedGoogle Scholar
  33. Burns, J.J.; Cucinell, S.A.; Koster, R. and Cowney, A.H.: Application of drug metabolism to drug toxicity studies. Annals of the New York Academy of Sciences 123: 272–286 (1965).Google Scholar
  34. Calabro, J.J.: Sulindac in the treatment of gout: Multicentre studies. European Journal of Rheumatology and Inflammation 1: 21–23 (1978).Google Scholar
  35. Capell, H.A.; Rennie, J.A.N.; Rooney, P.J.; Murdoch, R.M.; Hole, D.J.: Dick, W.C. and Buchanan, W.W.: Patient compliance: A novel method of testing non-steroidal anti-inflammatory analgesics in rheumatoid arthritis. Journal of Rheumatology 6: 584–593 (1979).PubMedGoogle Scholar
  36. Cardoe, N. and Fowler, P.D.: Butacote: A six-year follow-up of patients with gastric intolerance to other medications. Journal of International Medical Research 5(Suppl. 2): 59–66 (1977).PubMedGoogle Scholar
  37. Chalmers, A.; Offer, R. and Robinson, H.S.: A double-blind controlled study comparing the use of ASA and tolmetin with ASA and placebo in the treatment of rheumatoid arthritis. Current Therapeutic Research 24: 517–523 (1978).Google Scholar
  38. Christensen, L.K.; Hansen, J.M. and Kristensen, M.: Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 2: 1298–1301 (1963).PubMedGoogle Scholar
  39. Coe, F.L. and Kavalach, A.G.: Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. New England Journal of Medicine 291: 1344–1350 (1974).PubMedGoogle Scholar
  40. Coe, R.O. and Bull, F.E.: Cirrhosis associated with methotrexate treatment of psoriasis. Journal of the American Medical Association 206: 1515–1520 (1968).PubMedGoogle Scholar
  41. Cohen, A.S. and Calkins, E.: A controlled study of chloroquine as an anti-rheumatic agent. Arthritis and Rheumatism 1: 297–312 (1958).PubMedGoogle Scholar
  42. Cohen, A. and Garber, H.E.: Comparison of choline magnesium trisilicylate and acetylsalicylic acid in relation to fecal blood loss. Current Therapeutic Research 23: 187–193 (1978).Google Scholar
  43. Conn, H. and Blitzer, B.L.: Non-association of adrenocorticosteroid therapy and peptic ulcer. New England Journal of Medicine 294: 473–479 (1976).PubMedGoogle Scholar
  44. Co-operating Clinics Committee of the American Rheumatism Association: A three month trial of indomethacin in rheumatoid arthritis with special reference to analysis and inference. Clinical Pharmacology and Therapeutics 8: 11–37 (1967).Google Scholar
  45. Co-operating Clinics Committee of the American Rheumatism Association: A controlled trial of cyclophosphamide in rheumatoid arthritis. New England Journal of Medicine 283: 883–889 (1970).Google Scholar
  46. Co-operating Clinics Committee of the American Rheumatism Association: A controlled trial of high dose and low dose cyclophosphamide in 82 patients with rheumatoid arthritis (abstract). Arthritis and Rheumatism 15: 434 (1972).Google Scholar
  47. Croft, D.N.; Cuddigan, J.H.P. and Sweetland, C.: Gastric bleeding and benorylate, a new aspirin. British Medical Journal 3: 545–547 (1972).PubMedGoogle Scholar
  48. Crouzet, J.; Camus, J.P. and Leca, A.P.: Lupus induit par la D-penicillamine au cours du traitement de la polyarthrite rhumatoide. Deux observations et étude immunologique de ce traitement. Annales de Medecine Interne 125: 71–79 (1974).PubMedGoogle Scholar
  49. Currie, J.P.; Peebles-Brown, R.A. and Will, G.: Observations on the treatment of rheumatoid arthritis with butazolidin. Annals of the Rheumatic Diseases 12: 88–94 (1953).PubMedGoogle Scholar
  50. Cuisinaud, G.; Legheand, J.; Leorca, G.; Belkahia, C; Lejeune, E. and Sassard, J.: Pharmacokinetics of fenbufen in man. European Journal of Clinical Pharmacology 16: 59–61 (1979).PubMedGoogle Scholar
  51. Dall, J.L.C. and Keane, J.A.: Disturbances of pigmentation with chloroquine. British Medical Journal 1: 1387–1389 (1959).PubMedGoogle Scholar
  52. Danowski, T.S.; Bonesai, J.V.; Sutton, R.D.; Webster, M.W. and Sarver, M.E.: Probabilities of pituitary-adrenal responsiveness after steroid therapy. Annals of Internal Medicine 61: 11–26 (1964).PubMedGoogle Scholar
  53. Davies, D.S.: Phenylbutazone: Factors influencing plasma concentrations. Journal of International Medical Research 5(Suppl. 2): 15–19 (1977).PubMedGoogle Scholar
  54. Dayton, P.G.; Sicam, L.E. and Landrau, M.: Metabolism of sulfinpyrazone (Anuturane) and other thio analogues of Phenylbutazone in man. Journal of Pharmacology and Experimental Therapeutics 132: 287–290 (1961).PubMedGoogle Scholar
  55. Dayton, P.G.; Yu, T.F.; Chen, W.; Berger, L.; West, L.A. and Gutman, A.B.: The physiological disposition of probenecid, including renal clearance in man, studied by an improved method for its estimation in biological material. Journal of Pharmacology and Experimental Therapeutics 140: 278–286 (1963).PubMedGoogle Scholar
  56. Desai, S.N.: Sudden gigantism of breasts: Drug induced?: British Journal of Plastic Surgery 26: 371–372 (1973).PubMedGoogle Scholar
  57. De Schepper, P.J.; Tjandramaga, T.B.; Kram, P.R. and Getson, A.: Diflunisal (500mg bid): Effect upon gastrointestinal blood loss in man. Symposium on Diflunisal: New Perspectives in Analgesia, Abstract 18 (1978).Google Scholar
  58. Dessain, P.; Estabrooks, T.F. and Gordon, A.J.: Piroxicam in the treatment of osteoarthrosis: A multicentre study in general practice involving 1218 patients. Journal of International Medical Research 7: 335–343 (1979).PubMedGoogle Scholar
  59. Dick, W.C. and Buchanan, W.W.: Advances in the treatment of rheumatic disorders. Practitioner 207: 483–491 (1971).PubMedGoogle Scholar
  60. Dixon, M.F.: Paracetamol hepatotoxicity. Lancet 1: 35 (1976).Google Scholar
  61. Dixon, A. St. J.; Davies, J.; Dormandy, TL; Hamilton, EBD.; Holt, P.J.L.; Mason, R.M.; Thompson, M.; Weber, J.C.P. and Zutshi, D.W.: Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. Annals of the Rheumatic Diseases 34: 416–421 (1975).PubMedGoogle Scholar
  62. Donadio, J.V.; Holley, K.E.; Ferguson, R.H. and Ilstrup, D.M.: Treatment of diffuse proliferative lupus nephritis with Prednisone and combined Prednisone and cylophosphamide. New England Journal of Medicine 299: 1151–1155 (1978).PubMedGoogle Scholar
  63. Dorwart, B.B.; Gall, EP.; Schumacher, H.R. and Krauser, R.E.: Chrysotherapy in psoriatic arthritis. Arthritis and Rheumatism 21: 513–515 (1978).PubMedGoogle Scholar
  64. Duncan, H.: Bone dynamics in rheumatoid arthritis patients treated with adrenal corticosteroids. Arthritis and Rheumatism 10: 216–227 (1967).PubMedGoogle Scholar
  65. Dwosh, I.L.; Stein, H.B.; Urowitz, M.B.; Smythe, H.A.; Hunter, T. and Ogryzlo, M.A.: Azathioprine in early rheumatoid arthritis: Comparison with gold and chloroquine. Arthritis and Rheumatism 20: 685–692 (1977).PubMedGoogle Scholar
  66. Editorial: Chloroquine myopathy. British Medical Journal 2: 605 (1971).Google Scholar
  67. Editorial: Re-evaluation of parenteral pentazocine. Medical Letter on Drugs and Therapeutics 18: 46–47 (1976).Google Scholar
  68. Edmar, D.: Effects of salicylates on the gastric mucosa as revealed by roentgen examination. Acta Radiologica (Diagnosis) 11: 57–64 (1971).Google Scholar
  69. Ehrenbo, M.; Boreus, L.O. and Lonruth, U.: Bioavailability and first pass metabolism of oral pentazocine in man. Clinical Pharmacology and Therapeutics 22: 888–892 (1977).Google Scholar
  70. Elion, G.B.; Kovensky, A.; Hitching, G.H.; Metz, E. and Rundles, R.W.: Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochemical Pharmacology 15: 863–880 (1966).PubMedGoogle Scholar
  71. Elion, G.B.; Yu, T.F.; Gutman, A. and Hitchings, G.H.: Renal clearance of oxipurinol, the chief metabolite of allopurinol. American Journal of Medicine 45: 69–77 (1968).PubMedGoogle Scholar
  72. Emmerson, B.T.: A comparison of uricosuric agents in gout, with special reference to eulphinpyrazone. Medical Journal of Australia 1: 839–844 (1963).Google Scholar
  73. Emori, H.W.; Champion, G.D.; Bluestone, R. and Paulus, H.E.: Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Annals of the Rheumatic Diseases 32: 433–435 (1973a).PubMedGoogle Scholar
  74. Emori, H.W.; Paulus, H.E.; Bluestone, R. and Pearson, C.M.: The pharmacokinetics of indomethacin in serum (abstract). Clinical Pharmacology and Therapeutics 14: 134 (1973b).Google Scholar
  75. Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Report of a multicentre controlled trial. Annals of the Rheumatic Diseases 19: 95–116 (1960).Google Scholar
  76. Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Final report of a multicentre controlled trial. Annals of the Rheumatic Diseases 20: 315–333 (1961).Google Scholar
  77. Erlich, G.E. and Roth, S.: Rheumatoid arthritis: Long-term therapy with tolmetin sodium. Orthopaedic Digest 4: 16–24 (1976).Google Scholar
  78. Fauci, A.S.; Katz, P.; Haynes, B.F. and Wolff, S.M.: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. New England Journal of Medicine 301: 235–238 (1979).PubMedGoogle Scholar
  79. Feldges, D.H. and Barnes, C.G.: Treatment of psoriatic arthropathy with either azathioprine or methotrexate. Rheumatology and Rehabilitation 13: 120–124 (1974).PubMedGoogle Scholar
  80. Feldman, D.; Funder, J.W. and Edelman, J.S.: Subcellular mechanisms in the action of adrenal steroids. American Journal of Medicine 53: 545–560 (1972).PubMedGoogle Scholar
  81. Ferreira, M.L. and Buoniconti, A.: Trisomy after colchicine therapy. Lancet 2: 1304 (1968).PubMedGoogle Scholar
  82. Findlay, J.W.A.; Butz, R.F. and Welch, R.M.: Codeine kinetics as determined by radioimmunoassay. Clinical Pharmacology and Therapeutics 22: 439–446 (1977).PubMedGoogle Scholar
  83. Finkelstein, A.E.; Walz, D.T.; Batista, V.; Mizraji, M.; Roisman, F. and Misher, A.: Auranofin—New oral gold compound for treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 35: 251–257 (1976).PubMedGoogle Scholar
  84. Fletcher, M.R.; Loebl, W. and Scott, J.T.: Feprazone, a new anti-inflammatory agent: Studies of potency and gastro-intestinal tolerance. Ann. Rheum. Dis. 34: 190–194 (1975).PubMedGoogle Scholar
  85. Floman, Y.; Floman, U. and Zor, U.: Inhibition of Prostaglandin E release by anti-inflammatory steroids. Prostaglandins 11: 591–594 (1976).PubMedGoogle Scholar
  86. Fowler, P.D.: Marrow toxicity of the pyrazoles. Annals of the Rheumatic Diseases 26: 344–345 (1967).Google Scholar
  87. Fowler, P.D.: Voltarol: Diclofenac sodium. Clinics in Rheumatic Diseases 5: 427–464 (1979).Google Scholar
  88. Fraser, T.N.: Gold treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases 4: 71–75 (1945).PubMedGoogle Scholar
  89. Freedman, A. and Bach, F.: Mepacrine and rheumatoid arthritis. Lancet 2: 321 (1952).PubMedGoogle Scholar
  90. Freedman, A. and Steinberg, V.L.: Chloroquine in rheumatoid arthritis. A double blindfold trial of treatment for one year. Annals of the Rheumatic Diseases 19: 243–250 (1960).PubMedGoogle Scholar
  91. Fremont-Smith, P. and Baglis, T.B.: Salicylate therapy in rheumatoid arthritis. Journal of the American Medical Association 192: 1133–1135 (1965).PubMedGoogle Scholar
  92. Friedman, D.M. and Moore, M.E.: The efficacy of intra-articular corticosteroid for Osteoarthritis of the knee (abstract). Arthritis and Rheumatism 21: 556 (1978).Google Scholar
  93. Furst, D.E.; Levine, S.; Srinivasan, R.; Metzger, A.L.; Bangert, R. and Paulus, H.E.: A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arthritis and Rheumatism 20: 1473–1480 (1977).PubMedGoogle Scholar
  94. Gallagher, J.C.; Aaron, J.; Horsman, A.; Wilkinson, R. and Nordin, B.E.C.: Corticosteroid osteoporosis. Clinics in Endocrinology and Metabolism 2: 355–368 (1973).PubMedGoogle Scholar
  95. Gershwin, M.E.; Goetzl, E.J. and Steinberg, A.D.: Cyclophosphamide: Use in practice. Annals of Internal Medicine 80: 531–540 (1974).PubMedGoogle Scholar
  96. Gibaldi, M. and Schwartz, M.A.: Apparent effect of probenecid on distribution of penicillin in man. Clinical Pharmacology and Therapeutics 9: 345–349 (1968).PubMedGoogle Scholar
  97. Gibbons, R.B.: Complications of chrysotherapy. Archives of Internal Medicine 139: 343–346 (1979).PubMedGoogle Scholar
  98. Gibbs, K. and Walshe, J.M.: Studies in 35S-label led DL-penicillamine in patients with Wilson’s Disease. Quarterly Journal of Medicine 40: 275–287 (1971).PubMedGoogle Scholar
  99. Gibson, T.; Burry, H.C. and Ogg, C.: Goodpasture syndrome and D-penicillamine (corresp). Annals of Internal Medicine 84: 100 (1976).PubMedGoogle Scholar
  100. Girdwood, R.H.: Death after taking medicaments. British Medical Journal 1: 501–504 (1974).PubMedGoogle Scholar
  101. Glick, E.N.: Sulphinpyrazone in the treatment of arthritis associated with hyperuricaemia. Proceedings of the Royal Society of Medicine 54: 423–426 (1961).PubMedGoogle Scholar
  102. Godfrey, R.G.; Calabro, J.J.; Mills, D. and Maltz, B.A.: A double-blind crossover trial of aspirin, indomethacin and Phenylbutazone in ankylosing Spondylitis (abstract). Arthritis and Rheumatism 15: 110 (1972).Google Scholar
  103. Goldstein, G.: Mode of action of levamisole. Journal of the Rheumatic Diseases 5(Suppl. 4): 143–148 (1978).Google Scholar
  104. Goodwin, C.S. and Sparell, G.: Inhibition of dapsone excretion by probenecid. Lancet 2: 884–885 (1969).PubMedGoogle Scholar
  105. Gordon, B.L. and Yanagihara, R.: Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: A follow-up report of 16 patients under treatment for a minimum of four months. Annals of Allergy 39: 227–236 (1977).PubMedGoogle Scholar
  106. Graham, G.G.; Champion, G.D.; Day, R.O. and Pauli, P.D.: Patterns of plasma concentrations and urinary excretion of salicylates in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 22: 410–420 (1977).PubMedGoogle Scholar
  107. Greenberg, M.S. and Zambrano, S.S.: Aplastic agranulocytosis after allopurinol therapy. Arthritis and Rheumatism 15: 413–416 (1972).PubMedGoogle Scholar
  108. Greene, M.L.; Fujimoto, W.Y. and Seegmiller, J.E.: Urinary xanthine stones—a rare complication of allopurinol therapy. New England Journal of Medicine 280: 426–427 (1969).PubMedGoogle Scholar
  109. Grennan, D.M.; Ferry, D.G.; Ashworth, M.E.; Kenny, R.E. and MacKinnon, M.: The aspirin-ibuprofen interaction in rheumatoid arthritis. British Journal of Clinical Pharmacology 8: 497–503 (1979).PubMedGoogle Scholar
  110. Gumpel, J.M.: Deaths associated with gold treatment: A reassessment. British Medical Journal 1: 215–216 (1978).PubMedGoogle Scholar
  111. Gutman, A.B.: Treatment of primary gout: The present status. Arthritis and Rheumatism 8: 911–920 (1965).PubMedGoogle Scholar
  112. Gutman, A.B. and Yu, T-F.: Protracted uricosuric therapy in tophaceous gout. Lancet 2: 1258–1260 (1957).Google Scholar
  113. Hamilton, E.B.D. and Scott, J.T.: Hydroxychloroquine sulfate (‘Plaqueni‘) in treatment of rheumatoid arthritis. Arthritis and Rheumatism 5: 502–512 (1962).PubMedGoogle Scholar
  114. Hardin, J.G.: Controlled study of the long-term effects of ‘total hand’ injection (abstract). Arthritis and Rheumatism 22: 619 (1979).Google Scholar
  115. Harkness, A.J.L.; Burry, H.C. and Granarne, R.: A trial of feprazone in ankylosing Spondylitis. Rheumatology and Rehabilitation 16: 158–161 (1977).PubMedGoogle Scholar
  116. Hart, F.D. and Boardman, P.L.: Indomethacin: A new non-steroidal anti-inflammatory agent. British Medical Journal 2: 965–970 (1963).PubMedGoogle Scholar
  117. Hench, P.S.; Kendall, E.C.; Slocumb, C.H. and Polley, H.F.: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proceedings of the Staff Meeting of the Mayo Clinic 24: 181–197 (1949).Google Scholar
  118. Hicks, R.M.; Hanson, V. and Kornreich, H.K.: The use of gold in the treatment of juvenile rheumatoid arthritis (abstract). Arthritis and Rheumatism 13: 323 (1970).Google Scholar
  119. Hill, H.F.H.: Penicillamine in rheumatoid arthritis: Adverse effects. Scandinavian Journal of Rheumatology Supplement 28: 94–99 (1979).PubMedGoogle Scholar
  120. Hill, H.F.H.; Hill, A.G.S.; Day, AT.; Brown, R.M.; Golding, J.R. and Lyle, W.H.: Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between the standard and a response-related flexible regimen. Annals of the Rheumatic Diseases 38: 429–433 (1979).PubMedGoogle Scholar
  121. Hobbs, D.C. and Twomey, T.M.: Piroxicam pharmacokinetics in man: Aspirin and antacid studies. Journal of Clinical Pharmacology 19: 270–281 (1979).PubMedGoogle Scholar
  122. Hollander, J.L.; Jessar, R.A. and Brown, E.M.: Intra-synovial corticosteroid therapy: A decade of use. Bulletin on Rheumatic Diseases 11: 239–240 (1961a).PubMedGoogle Scholar
  123. Hollander, J.L.; Jessar, R.A.; Restifo, R.A. and Fort, H.J.: A new intra-articular steroid ester with longer effectiveness (abstract). Arthritis and Rheumatism 4: 422 (1961b).Google Scholar
  124. Holt, P.J.L. and Hawkins, C.F.: Indomethacin: Studies of absorption and the use of suppositories. British Medical Journal 1: 1354–1356 (1965).PubMedGoogle Scholar
  125. Hunder, G.G.; Sheps, S.G.; Allen, G.L. and Joyce, J.W.: Daily and alternate day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Annals of Internal Medicine 82: 613–618 (1975).PubMedGoogle Scholar
  126. Hunter, T.; Urowitz, M.B.; Duncan, D.A.; Smythe, H.A. and Ogryzlo, M.A.: Azathioprine in rheumatoid arthritis: A long-term follow-up study. Arthritis and Rheumatism 18: 15–20 (1975).PubMedGoogle Scholar
  127. Huskisson, E.C.: Simple analgesics for arthritis. British Medical Journal 4: 196–200 (1974).PubMedGoogle Scholar
  128. Huskisson, E.C.: Anti-inflammatory drugs. Seminars in Arthritis and Rheumatism 7: 1–20 (1977).PubMedGoogle Scholar
  129. Huskisson, E.C.: Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clinics in Rheumatic Diseases 5: 697–706 (1979).Google Scholar
  130. Huskisson, E.C. and Scott, J.: Sulindac. Trials of a new anti-inflammatory drug. Annals of the Rheumatic Diseases 37: 89–92 (1978).PubMedGoogle Scholar
  131. Huskisson, E.C.; Taylor, R.T.; Burston, D.; Chuter, P.J. and Hart, F.D.: Evening indomethacin in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 29: 393–396 (1970).PubMedGoogle Scholar
  132. Huskisson, E.C.; Woolf, D.L.; Balme, H.W.; Scott, J. and Franklyn, S.: Four new anti-inflammatory drugs: Responses and variations. British Medical Journal 1: 1048–1049 (1976).PubMedGoogle Scholar
  133. Inman, W.H.W.: Study of fatal bone marrow suppression with special reference to Phenylbutazone and oxyphenbutazone. British Medical Journal 1: 1500–1505 (1977).PubMedGoogle Scholar
  134. Irby, R.; Toone, E. and Owen, D.: Bone marrow depression associated with allopurinol therapy (abstract). Arthritis and Rheumatism 9: 860 (1966).Google Scholar
  135. Jaffe, I.A.: Rheumatoid arthritis with arteritis. Report of a case treated with penicillamine. Annals of Internal Medicine 61: 556–563 (1964).PubMedGoogle Scholar
  136. Jaffe, I.A.: D-penicillamine. Bulletin on the Rheumatic Diseases 28: 948–952 (1978).Google Scholar
  137. Jarzobski, J.; Ferry, J.; Wombolt, D.; Fitch, D.M. and Egan, J.D.: Vasculitis with allopurinol therapy. American Heart Journal 79: 116–121 (1970).PubMedGoogle Scholar
  138. Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 18: 173–187 (1959).Google Scholar
  139. Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 19: 331–337 (1960).Google Scholar
  140. Kaiser, D.G. and Glenn, E.M.: Aspirin-flurbiprofen interaction in the adjuvant-induced polyarthritic rat. Research Communications in Chemical Pathology and Pharmacology 9: 583–586 (1979).Google Scholar
  141. Kantor, T.G.: Ibuprofen. Annals of Internal Medicine 91: 877–882 (1979).PubMedGoogle Scholar
  142. Kantrowitz, F.; Robinson, D.R.; McGuire, M.B. and Levine, L.: Corticosteroids inhibit Prostaglandin synthesis in rheumatoid synovia. Nature 258: 737–739 (1975).PubMedGoogle Scholar
  143. Kay, A.G.L.: Myelotoxicity of gold. British Medical Journal 1: 1266–1268 (1976).PubMedGoogle Scholar
  144. Kay, A.G.L.: Myelotoxicity of D-penicillamine. Annals of the Rheumatic Diseases 38: 232–236 (1979).PubMedGoogle Scholar
  145. Kean, W.F. and Anastassiades, T.P.: Long-term chrysotherapy: Incidence of toxicity and efficacy during sequential time periods. Arthritis and Rheumatism 22: 495–501 (1979).PubMedGoogle Scholar
  146. Kean, W.F.; Dwosh, I.L.; Anastassiades, T.P.; Ford, P.M. and Kelly, H.G.: The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. Arthritis and Rheumatism 23: 158–164 (1980).PubMedGoogle Scholar
  147. Kenwright, S. and Levi, A.J.: Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications. Lancet 2: 1401–1405 (1973).PubMedGoogle Scholar
  148. Kersley, G.D.: Amethopterin (methotrexate) in connective tissue disease—psoriasis and polyarthritis. Annals of the Rheumatic Diseases 27: 64–66 (1968).PubMedGoogle Scholar
  149. Kincaid-Smith, P.: Analgesic nephropathy. Kidney International 13: 1–4 (1978).PubMedGoogle Scholar
  150. Klein, J.M. and Finland, O.: Ampicillin activity in vitro and absorption and excretion in normal young men. American Journal of the Medical Sciences 246: 10–26 (1963).PubMedGoogle Scholar
  151. Klein, R.G.; Arnaud, S.B.; Gallagher, J.C.; DeLuca, J.F. and Riggs, B.L.: Intestinal calcium absorption in exogenous hypercortisonism—role of 25-hydroxyvitamin D and corticosteroid dose. Journal of Clinical Investigation 60: 253–259 (1977).PubMedGoogle Scholar
  152. Klinefelter, H.F.: Re-institution of gold therapy in rheumatoid arthritis after mucocutaneous reactions. Journal of Rheumatology 2: 21–27 (1975).PubMedGoogle Scholar
  153. Klinenberg, J.R. and Miller, R.: Effect of corticosteroids on blood salicylate concentration. Journal of the American Medical Association 194: 601–604 (1965).PubMedGoogle Scholar
  154. Kwan, K.C.; Breault, G.O.; Umbenhauer, E.R.; McMahon, F.G. and Duggan, D.E.: Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. Journal of Pharmacokinetics and Biopharmaceutics 4: 255–280 (1976).PubMedGoogle Scholar
  155. Kwan, K.C.; Duggan, D.E.; Van Arman, E.G. and Shen, T.Y.: Sulindac: chemistry, pharmacology and pharmacokinetics. European Journal of Rheumatology and Inflammation 1: 9–11 (1978).Google Scholar
  156. Lawrence, J.S.: Comparative toxicity of gold preparations in treatment of rheumatoid arthritis. Annals of Rheumatic Diseases 35: 171–173 (1976).Google Scholar
  157. Lee, P.; Anderson, J.A.; Miller, J.; Webb, J. and Buchanan, W.W.: Evaluation of analgesic action and efficacy of anti-rheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. Journal of Rheumatology 3: 283–294 (1976).PubMedGoogle Scholar
  158. Leonards, JR.: Absence of gastrointestinal bleeding following administration of salicylsalicylic acid. Journal of Laboratory and Clinical Medicine 74: 911–914 (1969).PubMedGoogle Scholar
  159. Levin, H.M.; Bare, W.W. and Berry, F.N.: Acetaminophen with codeine for the relief of severe pain in post-partum patients. Current Therapeutic Research 16: 921–927 (1973).Google Scholar
  160. Levy, G.; Tsuchiya, T. and Amsel, L.P.: Limited capacity for salicylphenolic glucuronide formation and its effects on the kinetics of salicylate elimination in man. Clinical Pharmacology and Therapeutics 13: 258–268 (1972).PubMedGoogle Scholar
  161. Lewis, G.P.; Jusko, W.J.; Burke, C.W. and Graves, L.: Prednisone side effects and serum protein levels. Lancet 2: 778–780 (1971).PubMedGoogle Scholar
  162. Lidsky, M.D.; Stuart, J.T. and Billings, S.: A double-blind study of cyclophosphamide in rheumatoid arthritis. Arthritis and Rheumatism 16: 148–153 (1973).PubMedGoogle Scholar
  163. Liebling, M.R.; Altman, R.D.; Benedek, T.G.; Bennaham, D.A.; Blaschke, J.A.; Bower, R.J.; Calabro, J.J.; Caldwell, J.R.; Collins, R.L.; Felt, J.; Hamaty, D.; Jimeno, C.V.; Umbenhauer, E.R. and Wilkens, R.F.: A double-blind, multiclinic trial of sulindac (MK-231) in the treatment of ankylosing Spondylitis (abstract). Arthritis and Rheumatism 18: 411 (1975).Google Scholar
  164. Liegler, D.; Henderson, E.; Hahn, M.A. and Oliverio, V.: Renal clearance and in vivo protein binding of methotrexate in man and changes with salicylate administration (abstract). Proceedings of the American Association of Cancer Research 8: 41 (1967).Google Scholar
  165. Livanou, T.; Ferriman, D. and James, V.H.T.: Recovery of hypothalmic-pituitary-adrenal axis function after corticosteroid therapy. Lancet 2: 856–859 (1967).PubMedGoogle Scholar
  166. Loan, W.B. and Morrison, J.D.: Strong analgesics: Pharmacological and therapeutic aspects. Drugs 5: 108–143 (1973).Google Scholar
  167. Luukkainen, R.; Isomaki, H. and Kajander, A.: Effect of gold treatment on the progression of erosions in RA patients. Scandinavian Journal of Rheumatology 6: 123–127 (1977).PubMedGoogle Scholar
  168. MacKercher, P.A.; Ivey, K.J.; Baskin, W.N. and Krause, W.J.: Protective effect of Cimetidine on aspirin-induced gastric mucosal damage. Annals of Internal Medicine 87: 676–679 (1977).PubMedGoogle Scholar
  169. Mainland, D. and Sutcliffe, M.I.: Hydroxychloroquine sulfate in rheumatoid arthritis, a six month double-blind trial. Bulletin on the Rheumatic Diseases 13: 287–290 (1962).Google Scholar
  170. Malaviya, A.N.; Many, A. and Schwartz, R.S.: Treatment of dermatomyositis with methotrexate. Lancet 2: 485–488 (1968).PubMedGoogle Scholar
  171. Malawista, S.E.: Colchicine: A common mechanism for its anti-inflammatory and anti-mitotic effects. Arthritis and Rheumatism 11: 191–197 (1968).PubMedGoogle Scholar
  172. Manz, G. and Franke, M.: The treatment of ankylosing Spondylitis with TolectinR and indomethacin respectively: A randomized double-blind study. Therapiewoche 27: 2288–2297 (1977).Google Scholar
  173. Marbet, G.A.; Duckert, F.-, Walter, M.; Six, P. and Airenne, H.: Interaction study between phenprocoumon and flurbiprofen. Current Medical Research and Opinion 5: 26–31 (1977).PubMedGoogle Scholar
  174. Martin, J.H.; Gordon, M. and Wallace, R.: Methotrexate in psoriasis. Archives of Dermatology 96: 431–433 (1967).PubMedGoogle Scholar
  175. Mascarhenas, B.R.; Granda, J.L. and Freyberg, R.H.: Gold metabolism in patients with rheumatoid arthritis treated with gold compounds — re-investigated. Arthritis and Rheumatism 15: 391–402 (1972).Google Scholar
  176. Mason, M.; Currey, H.L.F.; Barnes, C.G.; Dunne, J.F.; Hazleman, B.L. and Strickland, I.D.: Azathioprine in rheumatoid arthritis. British Medical Journal 1: 420–422 (1969).PubMedGoogle Scholar
  177. McCarty, D.J.: Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide. Arthritis and Rheumatism 15: 157–173 (1972).PubMedGoogle Scholar
  178. McCarty, D.J. and Hogan, J.M.: Inflammatory reaction after intrasynovial injection of microcrystalline adrenocorticosteroid esters. Arthritis and Rheumatism 7: 359–367 (1964).PubMedGoogle Scholar
  179. McChesney, E.W.; Fasco, M.J. and Banks, W.F.: The metabolism of chloroquine in man during and after repeated oral dosage. Journal of Pharmacology and Experimental Therapeutics 158: 323–331 (1967).PubMedGoogle Scholar
  180. McGiff, J.C.; Crowshaw, K.; Terraguo, N.A.; Lonigro, A.J.; Strand, J.C.; Williamson, M.A.; Lee, J.B. and Ng, K.K.F.: Prostaglandin-like substances appearing in canine renal venous blood during renal ischemia. Circulation Research 27: 765–782 (1970).PubMedGoogle Scholar
  181. Merlin, H.E.: Azoospermia caused by colchicine. Fertility and Sterility 23: 180–181 (1972).PubMedGoogle Scholar
  182. Metzger, A.L.; Bohan, A.; Goldberg, L.S.; Bluestone, R. and Pearson, CM.: Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy. Annals of Internal Medicine 81: 182–189 (1974).PubMedGoogle Scholar
  183. Meyers, O.L.; Quantock, O.P.; Joubert, P.G.; Du, P.; Louw, D.F.; Marais, D.F.; McDonald Scott, W.A. and Müller, F.O.: A multicentre trial of Voltaren in the treatment of rheumatoid arthritis. South African Medical Journal 48: 2013–2017 (1974).PubMedGoogle Scholar
  184. Mielants, H. and Veys, EM.: A study of the hematological side-effects of levamisole in rheumatoid arthritis with recommendations. Journal of the Rheumatic Diseases 5(Suppl. 4): 77–83 (1978).Google Scholar
  185. Miller, R.R.: Propoxyphene: A review. American Journal of Hospital Pharmacy 34: 413–423 (1977).PubMedGoogle Scholar
  186. Millingen, K.S. and Suerth, E.: Peripheral neuromyopathy following chloroquine therapy. Medical Journal of Australia 1: 840–841 (1966).PubMedGoogle Scholar
  187. Mjolnerod, O.K.; Rasmussen, K.; Dommerud, S.A. and Gjeruldsen, ST.: Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1: 673–675 (1971).PubMedGoogle Scholar
  188. Moncada, S. and Vane, JR.: Mode of action of aspirin-like drugs. Advances in Internal Medicine 24: 1–22 (1979).PubMedGoogle Scholar
  189. Muller, F.O.; Hundt, H.K.L. and de Kock, A.C.: Decreased steady-state salicylic acid plasma levels associated with chronic aspirin ingestion. Current Medical Research and Opinion 3: 417–422 (1975).Google Scholar
  190. Multicentre Study Group: Levamisole in rheumatoid arthritis: a multicentre randomized double-blind study comparing two dosage schedules of levamisole and placebo. Lancet 2: 1007–1012 (1978a).Google Scholar
  191. Multicentre Study Group: A multicentre randomized double-blind study comparing two dosages of levamisole in rheumatoid arthritis. Journal of the Rheumatic Diseases 5(Suppl. 4): 5–10 (1978b).Google Scholar
  192. Multicentre Trial Group: Controlled trial of D(-)penicillamine in severe rheumatoid arthritis. Lancet 1: 275–280 (1973).Google Scholar
  193. Munthe, E.; Jellum, E. and Anseth, J.: Some aspects of the mechanism of action of penicillamine in rheumatoid arthritis. Scandinavian Journal of Rheumatology Supplement 28: 6–12 (1979).PubMedGoogle Scholar
  194. Murthy, M.H.V.; Rhymer, A.R. and Wright, V.: tIndomethacin or prednisolone at night in rheumatoid arthritis? Rheumatology and Rehabilitation 17: 8–13 (1978).PubMedGoogle Scholar
  195. Neild, G.H.; Gartner, H.V. and Bohle, A.: Penicillamine induced membranous glomerulonephritis. Scandinavian Journal of Rheumatology Supplement 28: 79–90 (1979).PubMedGoogle Scholar
  196. Nemati, M.; Kyle, M.C. and Fries, E.D.: Clinical study of ticrynafen: a new diuretic, antihypertensive, and uricosuric agent. Journal of the American Medical Association 237: 652–657 (1977).PubMedGoogle Scholar
  197. Nevins, M.; Berque, S.; Corwin, N. and Lyon, L.: Phenylbutazone and pulmonary edema (corresp). Lancet 2: 1358 (1969).PubMedGoogle Scholar
  198. Nuki, G.; Downie, W.W.; Dick, W.C, Whaley, K.; Spooner, JB.; Darby-Dowman, M.A. and Buchanan, W.W.: Clinical trial of pentazocine in rheumatoid arthritis — observations on the value of potent analgesics and placebos. Annals of the Rheumatic Diseases 32: 436–443 (1973).PubMedGoogle Scholar
  199. Nylander, U.: Ocular damage in chloroquine therapy. Acta Ophthalmologica 44: 335–348 (1966).PubMedGoogle Scholar
  200. O’Rourke, R.A. and Eckert, G.E.: Methotrexate-induced hepatic injury in an adult. Archives of Internal Medicine 113: 191–194 (1964).PubMedGoogle Scholar
  201. Patzschke, K.; Wegner, L.; Kaller, H. and Horster, F.A.: Pharkokinetische Untersuchungen nach oraler applikation von radioactiv markierten D-penicillamin an probanden. Zeitschrift fur Rheumatologie 36: 96–105 (1977).PubMedGoogle Scholar
  202. Paulus, H.E.; Siegel, M.; Mongan, E.; Okun, R. and Calabro, J.J.: Variations of serum concentrations and life of salicylate in patients with rheumatoid arthritis. Arthritis and Rheumatism 14: 527–532 (1971).PubMedGoogle Scholar
  203. Penner, J.A. and Abbrecht, P.H.: Lack of interaction between ibuprofen and warfarin. Current Therapeutic Research 18: 862–871 (1975).PubMedGoogle Scholar
  204. Penneys, N.S.; Ackerman, A.B. and Gottlieb, N.L.: Gold dermatitis: A clinical and histopathological study. Archives of Dermatology 109: 372–376 (1974).PubMedGoogle Scholar
  205. Percy, J.S.; Stephenson, P. and Thompson, M.: Indomethacin in the treatment of rheumatic diseases. Annals of the Rheumatic Diseases 23: 226–231 (1964).PubMedGoogle Scholar
  206. Perel, J.M.; Dayton, P.G.; Snell, M.M.; Yu, T-F. and Gutman, A.B.: Studies of interactions among drugs in man at the renal level. Probenecid and sulphinpyrazone. Clinical Pharmacology and Therapeutics 10: 834–840 (1969).PubMedGoogle Scholar
  207. Persellin, R.H. and Schmid, F.R.: The use of sulphinpyrazone in the treatment of gout reduces serum uric acid levels and diminishes severity of arthritic attacks, with freedom from significant toxicity. Journal of the American Medical Association 175: 971–975 (1961).PubMedGoogle Scholar
  208. Plotz, P.H.; Klippel, J.H.; Decker, J.L.; Grauman, D.; Wolff, B.; Brown, B.C. and Rutt, G.: Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Annals of Internal Medicine 91: 221–223 (1979).PubMedGoogle Scholar
  209. Popert, A.J.; Meyers, K.A.E.; Sharp, J. and Bier, F.: Chloroquine diphosphate in rheumatoid arthritis. Annals of the Rheumatic Diseases 20: 18–35 (1961).PubMedGoogle Scholar
  210. Radi, I.; Matoso, L.; Posmantir, A. and Papalexiou, P.: Safety and efficacy of Piroxicam in the treatment of ankylosing Spondylitis. European Journal of Rheumatology and Inflammation 1: 349–351 (1978).Google Scholar
  211. Reeback, J.S.; Chakraborty, J.; English, J.; Gibson, T. and Marks, V.: Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 39: 22–24 (1980).PubMedGoogle Scholar
  212. Rheinberger, K.: Efficacy and tolerance of Voltaren and indomethacin in patients with ankylosing Spondylitis. Therapiewoche 26: 2916–2920 (1976).Google Scholar
  213. Rhymer, A.H.: Sulindac. Clinics in Rheumatic Diseases 5: 553–568 (1979).Google Scholar
  214. Ridolfo, A.S.; Nickander, R. and Mikulaschek, W.M.: Fenoprofen and benoxaprofen. Clinics in Rheumatic Diseases 5: 393–410 (1979).Google Scholar
  215. Robertson, C.E.; Ford, M.J.; Van Someren, V.; Dlugolecka, M. and Prescott, L.F.: Mefenamic acid nephropathy. Lancet 2: 232–233 (1980).PubMedGoogle Scholar
  216. Rosenthal, M.: A critical review of the effect of levamisole in rheumatic diseases other than rheumatoid arthritis. Journal of the Rheumatic Diseases 5(Suppl. 4): 97–100 (1978).Google Scholar
  217. Rothermich, N.O.; Philips, U.K.; Bergen, W. and Thomas, M.H.: Chrysotherapy: A prospective study. Arthritis and Rheumatism 19: 1321–1327 (1976).PubMedGoogle Scholar
  218. Rubin, A.; Rodda, B.E.; Warrick, P.; Graber, C.M. and Ridolfo, A.S.: Interactions of aspirin with non-steroidal anti-inflammatory drugs in man. Arthritis arid Rheumatism 16: 635–645 (1973).Google Scholar
  219. Rudnicki, R.D.; Gresham, G.E. and Rothfield, N.F.: The efficacy of antimalarials in systemic lupus erythematosus. Journal of Rheumatology 2: 323–330 (1975).PubMedGoogle Scholar
  220. Rundles, R.W.; Metz, E.N. and Silberman, H.R.: Allopurinol in the treatment of gout. Annals of Internal Medicine 64: 229–258 (1966).PubMedGoogle Scholar
  221. Ryan, J.R.; Jain, A.K.; McMahon, F.G. and Vargas, R.: On the question of interaction between sulindac and tolbutamide in the control of diabetes. Clinical Pharmacology and Therapeutics 21: 231–233 (1977).PubMedGoogle Scholar
  222. Rynes, R.I.; Krohel, G.; Falbo, A.; Reinecke, R.D.; Wolfe, B. and Bartholomew, L.E.: Ophthalmologic safety of long-term hydroxychloroquine therapy. Arthritis and Rheumatism 22: 832–836 (1979).PubMedGoogle Scholar
  223. Samter, M.: The acetyl in aspirin. Annals of Internal Medicine 71: 208–209 (1969).PubMedGoogle Scholar
  224. Samter, M. and Beers, R.T.: Intolerance to aspirin: Clinical studies and consideration of its pathogenesis. Annals of Internal Medicine 68: 975–983 (1968).PubMedGoogle Scholar
  225. Sanchez, G.: Enhancement of heparin effect by probenecid. New England Journal of Medicine 292: 48 (letter) (1975).PubMedGoogle Scholar
  226. Sandvig, K.: Chloroquine (Resochin) effects on the cornea. Acta Ophthalmologica 44: 355–360 (1966).PubMedGoogle Scholar
  227. Schacter, D. and Manis, J.G.: Salicylate and salicyl conjugates: Fluorimetric estimation, biosynthesis, and renal excretion in man. Journal of Clinical Investigation 37: 800–807 (1958).Google Scholar
  228. Senary, W.L.; Lewis, R.J. and Rowland, L.: Warfarin-phenylbutazone interaction in man; a long-term multiple dose study. Research Communications in Chemical Pathology and Pharmacology 10: 663–668 (1975).Google Scholar
  229. Schein, P.S. and Winokur, J.H.: Immunosuppressive and cytotoxic therapy: long-term complications. Annals of Internal Medicine 82: 84–95 (1975).PubMedGoogle Scholar
  230. Schraeder, P.L.; Peters, H.A. and Dahl, D.S.: Polymyositis and penicillamine. Archives of Neurology 27: 456–457 (1972).PubMedGoogle Scholar
  231. Schuermans, Y.: Levamisole in rheumatoid arthritis. Lancet 1: 111 (1975).PubMedGoogle Scholar
  232. Segre, E.J.: Naproxen. Clinics in Rheumatic Diseases 5: 411–426 (1979).Google Scholar
  233. Segre, E.J.; Chaplin, M.; Forchielli, E.; Runkel, R. and Sevelius, H.: Naproxen-aspirin interactions in man. Clinical jpharmacology and Therapeutics 15: 374–379 (1974).Google Scholar
  234. Seidenfeld, A.M.; Smythe, H.A.; Ogryelo, M.A., Urowitz, M.B. and Dotten, D.A.: Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. Journal of Rheumatology 3: 295–304 (1976).PubMedGoogle Scholar
  235. Self, T.H.; Evans, W.E. and Ferguson, T.: Drug enhancement of warfarin activity. Lancet 2: 557–558 (1975).PubMedGoogle Scholar
  236. Shapiro, H.A.; Trowbridge, J.O.; Lee, J.C. and Maibach, H.I.: Liver disease in psoriatics — an effect of methotrexate therapy? Archives of Dermatology 110: 547–551 (1974).PubMedGoogle Scholar
  237. Sharp, J.T.; Lidky, M.D.; Duffy, J.; Thompson, H.K.; Person, B.D.; Masri, A.F. and Andrianakos, A.A.: Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis: relationship of serum gold levels to terapeutic response. Arthritis and Rheumatism 20: 1179–1187 (1977).PubMedGoogle Scholar
  238. Shearer, R.V. and Dubois, E.L.: Ocular changes induced by long-term hydroxychloroquine therapy. American Journal of Ophthalmology 64: 245–252 (1967).PubMedGoogle Scholar
  239. Sigler, J.W.; Bluhm, G.B.; Duncan, H.; Sharp, J.T.; Ensign, D.C. and McCrum, W.R.: Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Annals of Internal Medicine 80: 21–26 (1974).PubMedGoogle Scholar
  240. Silverberg, D.S.; Kidd, E.G. and Shnitka, T.K.: Gold nephropathy: A clinical and pathological study. Arthritis and Rheumatism 13: 812–825 (1970).PubMedGoogle Scholar
  241. Silvergleid, A.J. and Schier, S.L.: Acute myelogenous leukemia in two patients treated with azathioprine for non-malignant disease. American Journal of Medicine 57: 885–888 (1974).PubMedGoogle Scholar
  242. Silvoso, G.R.; Ivey, K.J., Butt, J.H.; Lockard, O.O.; Holt, S.D.; Sisk, C.; Baskin, W.N.; MacKercher, P.A. and Hewett, J.: Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Annals of Internal Medicine 91: 517–520 (1979).PubMedGoogle Scholar
  243. Skeith, M.D.; Simkin, P.A. and Healey, L.A.: Renal excretion of indomethacin and its inhibition by probenecid. Clinical Pharmacology and Therapeutics 9: 89–93 (1968).PubMedGoogle Scholar
  244. Sladek, N.E.: Therapeutic efficacy of cylophosphamide as a function of its metabolism. Cancer Research 32: 535–542 (1972).PubMedGoogle Scholar
  245. Smythe, C.J. and Percy, J.S.: Comparison of Phenylbutazone and indomethacin in acute gout. Annals of the Rheumatic Diseases 32: 351–353 (1973).Google Scholar
  246. Smythe, H.A.; Ogryzlo, M.A.; Murphy, E.A. and Mustard, J.F.: The effect of sulphinpyrazone (Anturan) on platelet economy and blood coagulation in man. Canadian Medical Association Journal 92: 818–821 (1965).PubMedGoogle Scholar
  247. Sokoloff, M.C.; Goldberg, L.S. and Pearson, C.M.: Treatment of corticosteroid-resistant Polymyositis with methotrexate. Lancet 1: 14–16 (1971).PubMedGoogle Scholar
  248. Solomon, L. and Abrams, G.: Voltaren in the treatment of rheumatoid arthritis. South African Medical Journal 48: 949–952 (1974).PubMedGoogle Scholar
  249. Spector, S.L.; Morris, H.G. and Seiner, J.C.: Pulmonary, Prostaglandin and clinical response of asthmatic patients with aspirin idiosyncracy to a new nonsteroidal anti-inflammatory substance compared to aspirin (abstract). Journal of Allergy and Clinical Immunology 63: 154–155 (1979).Google Scholar
  250. Standel, W.: The question of the drug treatment of ankylosing Spondylitis. Therapiewoche 27: 2273–2287 (1977).Google Scholar
  251. Staszewska-Barczak, J. and Vane, J.R.: The role of Prostaglandins in the local control of circulation. Clinical and Experimental Pharmacology and Physiology 2 (Suppl.): 71–78 (1975).PubMedGoogle Scholar
  252. Steigerwald, J.C.: Piroxicam and rheumatoid arthritis: A double-blind 16-week study comparing Piroxicam and indomethacin. European Journal of Rheumatology and Inflammation 1: 360–364 (1978).Google Scholar
  253. Stein, H.B.; Patterson, A.C.; Offer, R.C.; Atkins, C.J.; Teufel, A. and Robinson, H.S.: Adverse effects of D-penicillamine in rheumatoid arthritis. Annals of Internal Medicine 92: 24–29 (1980).PubMedGoogle Scholar
  254. Stephens, W.H.; El-Ghobarey, A.F.; MacLeod, M.M. and Buchanan, W.W.: A double-blind, crossover trial of mefenamic acid, sulindac and flurbiprofen in rheumatoid arthritis. Curr. Med. Res. Opin. 5: 754–758 (1979).PubMedGoogle Scholar
  255. Stevenson, D.D.; Arroyave, C.M.; Bhat, K.N. and Tan, E.M.: Oral aspirin challenges in asthmatic patients: A study of plasma histamine. Clinical Allergy 6: 493–505 (1976).PubMedGoogle Scholar
  256. Stockman, A.; Richter, D.; Barraclough, D.; Muirden, K.D.; Macdonald, I. and Kincaid-Smith, P.: Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis. Australia and New Zealand Journal of Medicine 9: 495–503 (1979).Google Scholar
  257. Stone, E.: An account of the success of the bark of the willow in the cure of agues. Philosophical Society Transactions 53: 195–200 (1763).Google Scholar
  258. Straitigos, J.D.; Bartsokas, S.K. and Capetanakis, J.: Further experiences with toxic epidermal necrolysis incriminating allopurinol, pyrazolone and derivatives. British Journal of Dermatology 86: 564–567 (1972).Google Scholar
  259. Sweetman, R.: Corticosteroid arthropathy and tendon rupture. Journal of Bone and Joint Surgery 51B: 397–398 (1969).Google Scholar
  260. Symoens, J. and Rosenthal, M.: Levamisole in the modulation of the immune response: The current experimental and clinical state. Journal of the Reticuloendothelial Society 21: 175–221 (1977).PubMedGoogle Scholar
  261. Szczeklik, A.; Gryglewski, R.J. and Czeniawska-Mysik, G.: Relationship of inhibition of Prostaglandin synthesis by analgesics to asthma attacks in aspirin sensitive patients. British Medical Journal 1: 67–69 (1975).PubMedGoogle Scholar
  262. Szczeklik, A.; Gryglewski, R.J.; Czeniawska-Mysik, G. and Zmuda, A.: Aspirin induced asthma. Journal of Allergy and Clinical Immunology 58: 10–18 (1976).PubMedGoogle Scholar
  263. Talbott, J.H.: Drug treatment of gout. Clinics in Rheumatic Diseases 5: 657–672 (1979).Google Scholar
  264. Tausch, G. and Eberl, R.: Efficacy, tolerance and safety of piroxicam in the treatment of acute gout. European Journal of Rheumatology and Inflammation 1: 365–368 (1978).Google Scholar
  265. Telhag, H.: Safety and efficacy of Piroxicam in the treatment of osteoarthrosis. European Journal of Rheumatology and Inflammation 1: 352–355 (1978).Google Scholar
  266. Tjandramaga, T.B.; Cucinell, S.A. and Israeli, Z.H.: Observations on the disposition of probenecid in patients receiving allopurinol. Pharmacology 8: 259–272 (1972).PubMedGoogle Scholar
  267. Tolman, E.L. and Partridge, P.: Multiple sites of interaction between Prostaglandins and non-steroidal anti-inflammatory agents. Prostaglandins 9: 349–359 (1975).PubMedGoogle Scholar
  268. Tornroth, T. and Skrifvars, B.: Gold nephropathy prototype of membranous glomerulonephritis. American Journal of Pathology 75: 573–584 (1974).Google Scholar
  269. Townes, A.S.; Sowa, J.M. and Shulman, L.E.: Controlled trial of cyclophosphamide in rheumatoid arthritis: An 18 month double-blind crossover study. Arthritis and Rheumatism 15: 129–130 (Abstract) (1972).Google Scholar
  270. Urowitz, M.B.; Hunter, T. and Bookman, A.A.: Azathioprine in rheumatoid arthritis: a double-blind study comparing full dose to half dose. Journal of Rheumatology 1: 274–281 (1974).Google Scholar
  271. Vane, JR.: Inhibition of Prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biology) 231: 232–235 (1971).Google Scholar
  272. Van Gerwen, F.; Van DerKoist, J.K. and Gribnau, F.W.J.: Double-blind trial of naproxen and Phenylbutazone in ankylosing Spondylitis. Annals of the Rheumatic Diseases 37: 85–88 (1978).PubMedGoogle Scholar
  273. Vesell, E.S.; Passananti, G.T. and Greene, F.E.: Impairment of drug metabolism in man by allopurinol and nortriptyline. New England Journal of Medicine 283: 1484–1488 (1970).PubMedGoogle Scholar
  274. Vesell, E.S.; Passananti, G.T. and Johnson, A.O.: Failure of indomethacin and warfarin to interact in normal human volunteers. Journal of Clinical Pharmacology 15: 486–495 (1975).PubMedGoogle Scholar
  275. Veys, E.M. and Mielants, H.: Experience and recommendations for treatment schedule of levamisole in rheumatoid arthritis. Journal of the Rheumatic Diseases 5(Suppl. 4): 31–41 (1978).Google Scholar
  276. Voipio, H.: Incidence of chloroquine retinopathy. Acta Ophthalmologica 44: 349–354 (1966).PubMedGoogle Scholar
  277. Wallace, S.L.: Colchicine and new anti-inflammatory drugs for the treatment of acute gout. Arthritis and Rheumatism 18: 847–851 (1975).PubMedGoogle Scholar
  278. Wallace, S.L.; Bernstein, D. and Diamond, H.: Diagnostic value of the colchicine therapeutic trial. Journal of the American Medical Association 199: 525–528 (1967).PubMedGoogle Scholar
  279. Wallace, S.L. and Ertel, N.H.: Occupancy approach to colchicine dosage. Lancet 2: 1250–1251 (1970).PubMedGoogle Scholar
  280. Walton, J.; Watson, B.S. and Ney, R.L.: Alternate-day vs. shorter interval steroid administration. Archives of Internal Medicine 126: 601–607 (1970).PubMedGoogle Scholar
  281. Weinberger, M.: Analgesic sensitivity in children with asthma. Pediatrics 62: (Suppl.): 910–916 (1978).PubMedGoogle Scholar
  282. Whitsett, T.L.; Barry, J.P.; Czerwinski, A.W.; Hall, W.H. and Hampton, J.W.: Tolmetin and warfarin: a clinical investigation to determine if interaction exists, in Tolmetin, A New Non-Steroidal Anti-Inflammatory Agent, pp.134–141 (Excerpta Medica, Princeton 1975).Google Scholar
  283. Wilkens, R.F. and Segre, E.J.: Combination therapy with naproxen and aspirin in rheumatoid arthritis. Arthritis and Rheumatism 19: 677–682 (1976).Google Scholar
  284. Winder, C.V.; Kaump, D.H.; Glazko, A.J. and Holmes, E.L.: Pharmacology of the fenamates. Annals of Physical Medicine Supplement: 7-49 (1966).Google Scholar
  285. Winter, C.A.; Risely, E.A. and Nuss, G.W.: Anti-inflammatory and anti-pyretic activities of indomethacin, 1-(p-chlorobenzyl) 5-methoxy-2-methylindole-3-acetic acid. Journal of Pharmacology and Experimental Therapeutics 141: 369–376 (1963).PubMedGoogle Scholar
  286. Wolff, S.M.; Fauci, A.S.; Horn, R.G. and Dale, D.C.: Wegener’s Granulomatosis. Annals of Internal Medicine 81: 513–525 (1974).PubMedGoogle Scholar
  287. Wyngaarden, J.B. and Kelley, W.N.: Gout and Hyperuricemia, pp.484–485 (Grune and Stratton, New York 1976).Google Scholar
  288. Yu, T.-F.; Burns, J.J. and Gutman, A.B.: Results of a clinical trial of G-28315, a sulfoxide analogue of Phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis and Rheumatism 1: 532–543 (1958).PubMedGoogle Scholar
  289. Yu, T.-F.; Dayton, P.G. and Gutman, A.B.: Mutual suppression of the uricosuric effects of sulphinpyrazone and salicylate: A study in interactions between drugs. Journal of Clinical Investigation 42: 1330–1339 (1963).Google Scholar
  290. Yu, T.-F. and Gutman, A.B.: Efficacy of colchicine prophylaxis in gout. Annals of Internal Medicine 55: 179–191 (1961).PubMedGoogle Scholar
  291. Zvaifler, N.J. and Rubin, M.: The metabolism of chloroquine. Arthritis and Rheumatism 5: 330 (Abstract) (1962).Google Scholar
  292. Zvaifler, N.J.; Rubin, M. and Bernstein, H.: Chloroquine metabolism — drug excretion and tissue deposition (abstract). Arthritis and Rheumatism 6: 799–800 (1963).Google Scholar

Copyright information

© Adis Press Australasia Pty Ltd. 1980

Authors and Affiliations

  • Gary L. Craig
    • 1
  • W. Watson Buchanan
    • 1
  1. 1.Department of RheumatologyMcMaster University Medical CentreHamiltonCanada

Personalised recommendations